Zepbound on Medicare 2026: $50 Coverage, KwikPen Restriction & Sleep Apnea Pathway

Last updated: May 11, 2026 · Reading time: 10 minutes

Zepbound is one of three GLP-1 medications eligible Medicare beneficiaries can get for $50 a month starting July 1, 2026, under the Medicare GLP-1 Bridge. Unlike Wegovy and Foundayo, Zepbound under the Bridge comes with a formulation restriction that’s easy to miss and easy to get wrong at the pharmacy: only the KwikPen version is covered, not the single-dose vials.

This page covers Zepbound specifically: what the KwikPen-only restriction means in practice, which doses qualify, how Zepbound’s coverage compares to standard Part D, and how it stacks up against Wegovy and Foundayo for someone choosing among the three. For the program rules in general, see our complete guide to the Medicare GLP-1 Bridge and the full eligibility breakdown.

Zepbound on Medicare: The 60-Second Summary

What Zepbound is: A weekly injectable GLP-1 medication (active ingredient: tirzepatide) made by Eli Lilly. The only dual GIP and GLP-1 receptor agonist among the three Bridge drugs.

Bridge coverage: Only the KwikPen formulation qualifies for $50 coverage. Single-dose vials and single-dose pens are NOT covered under the Bridge.

What it costs under the Bridge: $50 per month, defined as one KwikPen (which contains four weekly doses).

Doses covered: 2.5 mg (starting dose only), 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, all in KwikPen format.

Why KwikPen only: The Bridge is structured around a fixed monthly per-patient cost. The KwikPen delivers a full month of doses in one device, which simplifies billing and dispensing. Vials and single-dose pens use different supply economics.

The OSA wrinkle: Zepbound has a separate FDA-approved indication for moderate-to-severe obstructive sleep apnea in adults with obesity. The OSA indication is covered under standard Part D, not the Bridge.

[LEAD FORM PLACEHOLDER: “Check your eligibility for $50 Zepbound on Medicare”]

What Zepbound Actually Is

Zepbound contains tirzepatide, which is also the active ingredient in Mounjaro (Eli Lilly’s diabetes brand). The drug works on two different receptors instead of one: the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. Wegovy, Foundayo, and Ozempic only activate the GLP-1 receptor. The dual mechanism is the basis for tirzepatide’s stronger weight-loss results in head-to-head trials.

Zepbound was approved by the FDA for chronic weight management in November 2023. According to Eli Lilly’s announcement, Zepbound became the most prescribed weight management medication in the United States in 2025, overtaking Wegovy in market share. In December 2024, the FDA approved a second indication for Zepbound: moderate-to-severe obstructive sleep apnea in adults with obesity.

In the SURMOUNT-1 trial, adults taking Zepbound 15 mg weekly lost an average of 20.9% of their body weight over 72 weeks, compared to 3.1% with placebo. In SURMOUNT-5, a head-to-head trial against injectable Wegovy 2.4 mg, Zepbound produced an average weight loss of 50 pounds (20.2%) versus 33 pounds (13.7%) with Wegovy. Both trials lasted 72 weeks.

The KwikPen-Only Restriction Explained

Zepbound is available in three different delivery devices: a single-dose pen, a single-dose vial, and the multi-dose KwikPen. The KwikPen, approved by the FDA in February 2026 as a label expansion, holds four weekly doses in a single device. You inject from the same pen weekly for a month, then start a new pen.

Under the Medicare GLP-1 Bridge, only the KwikPen formulation qualifies for the $50 monthly price. According to Eli Lilly’s own savings page, Bridge coverage applies specifically to “eligible Medicare Part D patients with Zepbound KwikPen prescription for weight management.”

What this means in practice:

If you’re currently on Zepbound through LillyDirect’s single-dose vial program (the cash-pay route, $299-449 per month depending on dose), you won’t get $50 pricing until you switch to a KwikPen prescription.
If your prescriber writes for “Zepbound” without specifying KwikPen, the pharmacist may default to whichever format the pharmacy stocks, which might not be the KwikPen.
If you’re switching to Zepbound for the first time and want Bridge pricing, the prescription needs to explicitly state KwikPen.

The simplest way to avoid this trap: when your doctor writes your Zepbound prescription, ask them to specifically prescribe the KwikPen formulation. The KwikPen is the same drug, the same dose, and the same dosing schedule as the vials. The only difference is the delivery device.

For patients already on the vials through LillyDirect, talk to your prescriber about updating your prescription before July 1, 2026, so your first Bridge fill goes smoothly.

Zepbound KwikPen Doses Covered Under the Bridge

Zepbound is available in six doses, all in KwikPen format under the Bridge:

2.5 mg: starting dose only, not approved for long-term maintenance. Used for the first month to allow your body to adjust before stepping up.
5 mg: first maintenance dose option
7.5 mg: second maintenance dose option
10 mg: third maintenance dose option
12.5 mg: fourth maintenance dose option
15 mg: maximum dose

Each KwikPen contains four weekly doses, defined as a 28-day supply. Your monthly $50 covers one KwikPen, regardless of dose. The starting protocol typically involves four weeks at 2.5 mg, then four weeks at 5 mg, with possible further escalation based on tolerability and weight-loss response.

Higher doses tend to produce greater weight loss. In SURMOUNT-1, the 5 mg dose produced 15.0% weight loss, the 10 mg dose produced 19.5%, and the 15 mg dose produced 20.9%. Side effects (mostly gastrointestinal) tend to be more frequent at higher doses, which is why most prescribers titrate slowly.

The Bridge covers whichever dose your prescriber writes for. Dose changes within a billing cycle require a new prescription but not a new prior authorization.

The Obstructive Sleep Apnea Wrinkle

This is the Zepbound equivalent of Wegovy’s cardiovascular indication. The drug is FDA-approved for two distinct uses, and they get covered through different Medicare pathways.

For chronic weight management (obesity indication): Covered under the Bridge at $50 per month for eligible beneficiaries.

For moderate-to-severe obstructive sleep apnea in adults with obesity: Covered under standard Part D rules, not the Bridge. Your Part D plan’s copay applies, which varies widely depending on formulary placement.

The OSA indication came from the SURMOUNT-OSA trials, which showed substantial reductions in breath disruptions per hour and meaningful weight loss in patients with OSA and obesity. Eli Lilly positioned it as the first FDA-approved prescription medicine for moderate-to-severe OSA in this population.

If you have both obesity and OSA, you can technically be prescribed Zepbound for either indication. Which indication appears on the prior authorization determines which pathway you’re routed through. Talk to your prescriber about whether the Bridge ($50 flat) or Part D coverage for the OSA indication (variable copay, but counts toward your Part D protections) makes more financial sense for your situation.

Note: Zepbound is the only one of the three Bridge drugs with the OSA indication. Wegovy and Foundayo are approved for obesity and (for Wegovy) cardiovascular risk reduction, but not for OSA.

Zepbound vs. Wegovy vs. Foundayo: How They Compare

All three drugs are covered under the Bridge for $50, so cost isn’t the differentiator. The choice comes down to clinical factors, side effect tolerance, and personal preference.

Zepbound produces the most weight loss on average of the three. Dual GIP/GLP-1 mechanism. Weekly injection only (KwikPen formulation only under Bridge). The only one with the OSA indication. Most prescribed weight management medication in 2025.

Wegovy is the only one with an FDA-approved cardiovascular indication, which matters if you have established heart disease. Available as a weekly injection or a daily pill. Slightly less weight loss on average than Zepbound in head-to-head trials.

Foundayo is a daily pill with no food or water restrictions, which makes it the easiest of the three to take. Newest of the three (approved April 2026). Produces less weight loss than the injections but is well-tolerated.

A simplified decision frame: if you have heart disease and obesity, lean toward Wegovy. If you have OSA and obesity, lean toward Zepbound. If you’d struggle with weekly injections or with the Wegovy pill’s empty-stomach restrictions, lean toward Foundayo. If none of those apply and you want the strongest weight-loss results, lean toward Zepbound.

Your prescriber’s preference matters too. Some clinicians have more experience with one drug than another, which affects how they handle dose titration and side effect management. For a deeper comparison, see Wegovy vs. Zepbound vs. Foundayo: which to ask your doctor about (coming soon).

How to Get Zepbound KwikPen Under the Bridge

The mechanics are the same as for any Bridge medication, with two Zepbound-specific considerations: the KwikPen requirement and the OSA indication question.

Confirm you have Medicare Part D. Standalone PDP or Medicare Advantage with drug coverage.
Talk to your doctor specifically about KwikPen. If you want Bridge pricing, your prescription needs to specify the KwikPen formulation. If you also have OSA, ask whether the obesity indication (Bridge) or the OSA indication (Part D) is more financially favorable given your plan.
Your doctor submits a prior authorization to the CMS central processor, not your Part D plan.
Once approved, fill at any pharmacy. The pharmacist bills the central processor using BIN 028918 and PCN MEDDGLP1BR.
Pay $50 at the counter.

If you’re currently using Zepbound vials through LillyDirect and want to switch to the KwikPen for Bridge coverage, ask your prescriber to send a new prescription specifying KwikPen to a pharmacy of your choice. Lilly maintains direct support for KwikPen questions at the LillyDirect line: 1-844-LLYDIR1 (1-844-559-3471).

Zepbound Side Effects and Considerations

Zepbound carries a boxed warning for thyroid C-cell tumors based on rat studies. People with a personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2, should not use Zepbound.

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion. In SURMOUNT-1 and SURMOUNT-2, severe gastrointestinal adverse reactions occurred in 1.7% of patients on 5 mg, 2.5% on 10 mg, and 3.1% on 15 mg, compared to 1.0% on placebo. The rate of severe GI events scaled with dose, which is part of why slow titration matters.

Other potential side effects include pancreatitis, gallbladder problems, severe dehydration leading to kidney problems, low blood sugar (in diabetic patients), and reduced effectiveness of oral hormonal contraceptives (use barrier methods for four weeks after starting Zepbound and after each dose escalation).

This page is not medical advice. Discuss your full medical history, current medications, and any contraindications with your prescriber before starting Zepbound.

Frequently Asked Questions

Why are Zepbound vials not covered under the Bridge?

CMS designed the Bridge around a single monthly per-patient cost. The KwikPen delivers one month’s worth of doses in one device, which simplifies the cost calculation. Vials are dispensed weekly and have different supply economics. Eli Lilly negotiated the Bridge agreement around the KwikPen format specifically.

Can I switch from Wegovy to Zepbound under the Bridge?

Yes, with a new prescription and a new prior authorization. There’s no penalty for switching. Your prescriber decides whether switching is clinically appropriate.

Is Zepbound the same as Mounjaro?

Same active ingredient (tirzepatide), different FDA-approved uses. Mounjaro is approved for Type 2 diabetes. Zepbound is approved for chronic weight management and OSA. Mounjaro is covered through standard Part D for diabetes; it’s not part of the Bridge.

What if my pharmacy doesn’t stock the KwikPen?

The KwikPen has been available since April 2026, but inventory at retail pharmacies varies. If your pharmacy doesn’t stock it, ask them to order it (typically arrives within 1-3 business days) or ask your prescriber to transfer the prescription to a pharmacy that does.

Do I need a new prior authorization if my dose changes?

No. Prior authorization covers Zepbound for the duration of the demonstration. Dose changes are handled at the prescription level. Your prescriber writes a new prescription for the new dose, and your $50 monthly cost stays the same.

What happens to Zepbound coverage when the Bridge ends in 2027?

Unknown. The Bridge expires December 31, 2027, and transitions to the BALANCE Model in 2028, which would shift coverage back into Part D. Whether Zepbound stays at $50 or returns to higher pricing under Part D depends on negotiations that haven’t happened yet.

Sources and References

This guide is for informational purposes only and is not medical advice. Zepbound carries serious safety considerations including a boxed warning. Discuss your full medical history and current medications with a licensed healthcare provider before starting any GLP-1 therapy. Weight Loss RX Guide is not affiliated with CMS, Medicare, or Eli Lilly. We may receive compensation when readers connect with services through links on this site; see our affiliate disclosure for details.